205 related articles for article (PubMed ID: 29552766)
1. Randomized controlled trial of endostar combined with cisplatin/ pemetrexed chemotherapy for elderly patients with advanced malignant pleural effusion of lung adenocarcinoma.
Jie Wang X; Miao K; Luo Y; Li R; Shou T; Wang P; Li X
J BUON; 2018; 23(1):92-97. PubMed ID: 29552766
[TBL] [Abstract][Full Text] [Related]
2. Bevacizumab plus chemotherapy in nonsquamous non-small cell lung cancer patients with malignant pleural effusion uncontrolled by tube drainage or pleurodesis: A phase II study North East Japan Study group trial NEJ013B.
Noro R; Kobayashi K; Usuki J; Yomota M; Nishitsuji M; Shimokawa T; Ando M; Hino M; Hagiwara K; Miyanaga A; Seike M; Kubota K; Gemma A;
Thorac Cancer; 2020 Jul; 11(7):1876-1884. PubMed ID: 32421226
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of endostar combined with cisplatin in treatment of non-small cell lung cancer with malignant pleural effusion: A meta-analysis.
Hu Y; Zhou Z; Luo M
Medicine (Baltimore); 2022 Dec; 101(52):e32207. PubMed ID: 36595983
[TBL] [Abstract][Full Text] [Related]
4. Effects of intracavitary administration of Endostar combined with cisplatin in malignant pleural effusion and ascites.
Zhao WY; Chen DY; Chen JH; Ji ZN
Cell Biochem Biophys; 2014 Sep; 70(1):623-8. PubMed ID: 24920191
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of bevacizumab with carboplatin-pemetrexed in non-squamous non-small cell lung carcinoma patients with malignant pleural effusions: North East Japan Study Group Trial NEJ013A.
Usui K; Sugawara S; Nishitsuji M; Fujita Y; Inoue A; Mouri A; Watanabe H; Sakai H; Kinoshita I; Ohhara Y; Maemondo M; Kagamu H; Hagiwara K; Kobayashi K;
Lung Cancer; 2016 Sep; 99():131-6. PubMed ID: 27565928
[TBL] [Abstract][Full Text] [Related]
6. Intrapleural combination therapy with bevacizumab and cisplatin for non-small cell lung cancer‑mediated malignant pleural effusion.
Du N; Li X; Li F; Zhao H; Fan Z; Ma J; Fu Y; Kang H
Oncol Rep; 2013 Jun; 29(6):2332-40. PubMed ID: 23525453
[TBL] [Abstract][Full Text] [Related]
7. Intrapleural infusion of tumor cell-derived microparticles packaging methotrexate or saline combined with pemetrexed-cisplatin chemotherapy for the treatment of malignant pleural effusion in advanced non-squamous non-small cell lung cancer: A double-blind, randomized, placebo-controlled study.
Dong X; Huang Y; Yi T; Hu C; Gao Q; Chen Y; Zhang J; Chen J; Liu L; Meng R; Zhang S; Dai X; Fei S; Jin Y; Yin P; Hu Y; Wu G
Front Immunol; 2022; 13():1002938. PubMed ID: 36275698
[TBL] [Abstract][Full Text] [Related]
8. Effect of thoracic hyperthermic perfusion with recombinant human endostatin plus nedaplatin in treating pleural effusion in patients with advanced non-small cell lung cancer.
Chen L; Zhu X; Li D; Cai X
J BUON; 2020; 25(6):2643-2649. PubMed ID: 33455108
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of bevacizumab combined with chemotherapy in lung adenocarcinoma-induced malignant pleural effusion.
Tao H; Meng Q; Li M; Shi L; Tang J; Liu Z
Thorac Cancer; 2018 Feb; 9(2):298-304. PubMed ID: 29297985
[TBL] [Abstract][Full Text] [Related]
10. Thoracic perfusion of recombinant human endostatin (Endostar) combined with chemotherapeutic agents versus chemotherapeutic agents alone for treating malignant pleural effusions: a systematic evaluation and meta-analysis.
Biaoxue R; Xiguang C; Hua L; Wenlong G; Shuanying Y
BMC Cancer; 2016 Nov; 16(1):888. PubMed ID: 27842514
[TBL] [Abstract][Full Text] [Related]
11. Salvage treatment with irinotecan/cisplatin versus pemetrexed/cisplatin in patients with non-small cell lung cancer pre-treated with a non-platinum-based regimen in the first-line setting: a randomized phase II study of the Hellenic Oncology Research Group (HORG).
Kentepozidis N; Economopoulou P; Christofyllakis C; Chelis L; Polyzos A; Vardakis N; Koinis F; Vamvakas L; Katsaounis P; Kalbakis K; Nikolaou C; Georgoulias V; Kotsakis A
Clin Transl Oncol; 2017 Mar; 19(3):317-325. PubMed ID: 27492015
[TBL] [Abstract][Full Text] [Related]
12. [A multicenter, randomized, double-blind, placebo-controlled safety study to evaluate the clinical effects and quality of life of paclitaxel-carboplatin (PC) alone or combined with endostar for advanced non-small cell lung cancer (NSCLC)].
Han BH; Xiu QY; Wang HM; Shen J; Gu AQ; Luo Y; Bai CX; Guo SL; Liu WC; Zhuang ZX; Zhang Y; Zhao YZ; Jiang LY; Shi CL; Jin B; Zhou JY; Jin XQ
Zhonghua Zhong Liu Za Zhi; 2011 Nov; 33(11):854-9. PubMed ID: 22335953
[TBL] [Abstract][Full Text] [Related]
13. A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of paclitaxel-carboplatin alone or with endostar for advanced non-small cell lung cancer.
Han B; Xiu Q; Wang H; Shen J; Gu A; Luo Y; Bai C; Guo S; Liu W; Zhuang Z; Zhang Y; Zhao Y; Jiang L; Zhou J; Jin X
J Thorac Oncol; 2011 Jun; 6(6):1104-9. PubMed ID: 21532504
[TBL] [Abstract][Full Text] [Related]
14. Cisplatin/Pemetrexed Followed by Maintenance Pemetrexed Versus Carboplatin/Paclitaxel/Bevacizumab Followed by Maintenance Bevacizumab in Advanced Nonsquamous Lung Cancer: The GOIM (Gruppo Oncologico Italia Meridionale) ERACLE Phase III Randomized Trial.
Galetta D; Cinieri S; Pisconti S; Gebbia V; Morabito A; Borsellino N; Maiello E; Febbraro A; Catino A; Rizzo P; Montrone M; Misino A; Logroscino A; Rizzi D; Di Maio M; Colucci G
Clin Lung Cancer; 2015 Jul; 16(4):262-73. PubMed ID: 25582493
[TBL] [Abstract][Full Text] [Related]
15. Three-Year Follow-Up of a Randomized Phase II Trial on Refinement of Early-Stage NSCLC Adjuvant Chemotherapy with Cisplatin and Pemetrexed versus Cisplatin and Vinorelbine (the TREAT Study).
Kreuter M; Vansteenkiste J; Fischer JR; Eberhardt WE; Zabeck H; Kollmeier J; Serke M; Frickhofen N; Reck M; Engel-Riedel W; Neumann S; Thomeer M; Schumann C; De Leyn P; Graeter T; Stamatis G; Griesinger F; Thomas M;
J Thorac Oncol; 2016 Jan; 11(1):85-93. PubMed ID: 26762743
[TBL] [Abstract][Full Text] [Related]
16. CHAMP: A Phase II Study of Panitumumab With Pemetrexed and Cisplatin Versus Pemetrexed and Cisplatin in the Treatment of Patients With Advanced-Stage Primary Nonsquamous Non-Small-Cell Lung Cancer With Particular Regard to the KRAS Status.
Schuette W; Behringer D; Stoehlmacher J; Kollmeier J; Schmager S; Fischer von Weikersthal L; Schumann C; Buchmann J
Clin Lung Cancer; 2015 Nov; 16(6):447-56. PubMed ID: 26094080
[TBL] [Abstract][Full Text] [Related]
17. Phase II Study of the Efficacy and Safety of High-dose Pemetrexed in Combination with Cisplatin
He Q; Bi X; Ren C; Wang Y; Zou P; Zhang H; Chi N; Xiu C; Wang Y; Tao R
Anticancer Res; 2017 Aug; 37(8):4711-4716. PubMed ID: 28739776
[TBL] [Abstract][Full Text] [Related]
18. Thoracic perfusion of lobaplatin combined with endostar for treating malignant pleural effusions: A meta-analysis and systematic review.
Wang CQ; Liu FY; Wang W
Medicine (Baltimore); 2022 Oct; 101(40):e30749. PubMed ID: 36221355
[TBL] [Abstract][Full Text] [Related]
19. Endostar (rh-endostatin) versus placebo in combination with vinorelbine plus cisplatin chemotherapy regimen in treatment of advanced non-small cell lung cancer: A meta-analysis.
An J; Lv W
Thorac Cancer; 2018 May; 9(5):606-612. PubMed ID: 29575575
[TBL] [Abstract][Full Text] [Related]
20. [Efficacy of endostar combined with chemotherapy in multi-cycle treatment of patients with advanced non-small cell lung cancer].
Li N; Jin ZL; Liu ZJ; Wang J; Li K
Zhonghua Zhong Liu Za Zhi; 2011 Dec; 33(12):937-42. PubMed ID: 22340106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]